Clinical trial
Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in…
NCT00192504 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00192504 |
|---|---|
| Title | Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection |
| Official title | A Phase 1, Randomized, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Single Intravenous Dose of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody to Respiratory Syncytial Virus (RSV), in Otherwise Healthy Children… |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Respiratory Syncytial Virus Prophylaxis |
| Intervention type | Biological, Other |
| Interventions | Motavizumab, Placebo |
| Enrollment | 31 |
| Start date | Mar 1, 2004 |
| Primary completion | Jan 1, 2005 |
| Completion | Jan 1, 2005 |
| First posted | Sep 19, 2005 |
| Last update posted | Oct 8, 2021 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: